PHAM QUANG X (CEO and Chairman) sold 8.9% of their position (11.44K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $39.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/24/2026ACC: 0001213900-26-071578
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-11.44K
Net shares
Net seller
$39.8K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
11.44K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−9.17K
Price / share
$3.55
Trade value
$32.54K
% of position
7.1%
6/22/2026
128.59K→119.42K
Common Stock
Direct
Shares
−2.28K
Price / share
$3.20
Trade value
$7.29K
% of position
1.9%
6/23/2026
119.42K→117.14K
Total
Net shares
−11.44K
Net value
-$39.83K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/22/2026 | S · Sale | −9.17K | $3.55 | $32.54K | 7.1% | 128.59K | 119.42K |
| Common Stock Direct | 6/23/2026 | S · Sale | −2.28K | $3.20 | $7.29K | 1.9% | 119.42K | 117.14K |
| Total | −11.44K | -$39.83K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported